Zenalux Biomedical has released its Zenascope PC1 spectrometer, a pre-clinical tool that uses visible to ultra-violet light to measure hemoglobin and saturation, as well as the cellular density and fibrous count of tissues. Though currently not available for clinical use, the device may be able to detect tumors based on tissue spectrometry and so for now will help researchers in developing cures.
From the announcement:
The system is a specialized, real-time, diagnostic device that shines white light on opaque target media and then measures and analyzes the reflected signal. Proprietary algorithms and standardized measurement hardware achieve rapid, quantitative analysis of targeted endpoints including hemoglobin concentration, hemoglobin saturation and scattering (a measure of cell density and necrosis). The system can also easily be tuned to include additional absorbers of interest. This unique capability is expected to enable improved diagnosis, better treatment and ultimately cost reduction in the health care system. Application areas currently include accelerating feedback in drug discovery; breast tumor margin assessment; response to therapy; breast biopsy; cervical cancer detection; and head and neck cancer detection.
Product page: ZENASCOPE PC1…
Announcement: Zenalux Biomedical Unveils the Zenascope PC1…